| | Title | Author(s) | Year | View Count | | 1 |  | Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B | Gish, RG; Chang, TT; Lai, CL; De Man, R; Gadano, A; Poordad, F; Yang, J; BrettSmith, H; Tamez, R | 2010 | 311 |
| 2 | | Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B | Fung, J; Lai, CL; Yuen, MF | 2010 | 42 |
| 3 | | Safety evaluation of telbivudine | But, DYK; Yuen, MF; Fung, J; Lai, CL | 2010 | 60 |
| 4 |  | Transfusion-refractory anaemia in liver cirrhosis | So, JCC; Hwang, YY; Shek, WH; Lam, CCK; Lai, CL; Kwong, YL | 2010 | 534 |
| 5 | | Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation | Mukaide, M; Tanaka, Y; ShinI, T; Yuen, MF; Kurbanov, F; Yokosuka, O; Sata, M; Karino, Y; Yamada, G; Sakaguchi, K; Orito, E; Inoue, M; Baqai, S; Lai, CL; Mizokami, M | 2010 | 161 |
| 6 |  | Updates in the treatment of chronic hepatitis C | Fung, JYY; Lai, CL; Yuen, RMF | 2010 | 54 |
| 7 | | Systemic corticosteroid and reactivation of chronic hepatitis B | Lai, CL; Yuen, MF | 2010 | 97 |
| 8 | | Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B | Chang, TT; Lai, CL; Yoon, SK; Lee, SS; Coelho, HSM; Carrilho, FJ; Poordad, F; Halota, W; Horsmans, Y; Tsai, N; Zhang, H; Tenney, DJ; Tamez, R; Iloeje, U | 2010 | 100 |
| 9 | | Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease | Yuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL | 2010 | 58 |
| 10 | | Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage | Wu, IC; Lai, CL; Bui Han, SH; Han, KH; Gordon, SC; Chao, YC; Tan, CK; Sievert, W; Tanwandee, T; Xu, D; Neo, BL; Chang, TT | 2010 | 48 |
| 11 | | The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report | Antaki, N; Craxi, A; Kamal, S; Moucari, R; Van Der Merwe, S; Haffar, S; Gadano, A; Zein, N; Lai, CL; Pawlotsky, J; Heathcote, EJ; Dusheiko, G; Marcellin, P | 2010 | 66 |
| 12 | | Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B | Chang, TT; Liaw, YF; Wu, SS; Schiff, E; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, Z; Chi, YC; Zhang, H; Hindes, R; Iloeje, U; Beebe, S; Kreter, B | 2010 | 78 |
| 13 | | Natural history of chronic hepatitis C: Genotype 1 versus genotype 6 | Seto, WK; Lai, CL; Fung, J; Hung, I; Yuen, J; Young, J; Wong, DKH; Yuen, MF | 2010 | 3,020 |
| 14 | | Profile of pre-S deletions in the natural history of chronic hepatitis B infection. | Yeung, P; Wong, DK; Lai, CL; Fung, J; Seto, WK; Yuen, MF | 2010 | 293 |
| 15 | | Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis | Fung, J; Lai, CL; Chan, SC; But, D; Seto, WK; Cheng, C; Wong, DKH; Lo, CM; Fan, ST; Yuen, MF | 2010 | 578 |
| 16 | | Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B | Fung, J; Lai, CL; But, D; Hsu, A; Seto, WK; Cheng, C; Wong, DKH; Yuen, MF | 2010 | 837 |
| 17 | | Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: A study of a large blood donor population | Yuen, MF; Lee, CK; Wong, DKH; Fung, J; Hung, I; Hsu, A; But, DYK; Cheung, TK; Chan, P; Yuen, JCH; Fung, FKC; Seto, WK; Lin, CK; Lai, CL | 2010 | 631 |
| 18 | | Lamivudine therapy for chronic hepatitis B | Seto, WK; Lai, CL; Fung, J; Yuen, RMF | 2010 | 12 |
| 19 | | The saga of entecavir | Lai, CL; Yuen, MF | 2009 | 31 |
| 20 | | Hepatitis B and C virus-related carcinogenesis | Fung, J; Lai, CL; Yuen, MF | 2009 | 46 |
|
